Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/Neu oncogene products using ex-vivo peptide loaded dendritic cells

Advances in Experimental Medicine and Biology

Volumn 417, Issue , 1997, Pages 583-589

  Navabi, H ^a   Jasani, B ^b   Adams, M ^a   Evans, A S ^b   Mason, M ^a   Crosby, T ^a   Borysiewicz, L ^b  

^a Velindre NHS Trust   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; TUMOR ANTIGEN; VIRUS PROTEIN;

ANTIGEN EXPRESSION; CANCER CELL DESTRUCTION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; WART VIRUS;

HUMAN PAPILLOMAVIRUS TYPES;

EID: 0030882439     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9966-8_94     Document Type: Conference Paper

References (9)

1. Saullusto F, Lanzavecchia A, (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin-4 and down regulated by tumour necrosis factor alpha. J Exp Med 179: 1109-1118.
2. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacker B, Konwalinka G, Fritsch PO, Steinmanand Schuler G, (1994). Proliferating dendritic cell progenitors in human blood. J Exp Med 180, 83-93
3. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, (1995). Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nature Medicine 1(12): 1297-1302
4. Dsis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Lydon N, McGlynn E, Moe R, Cheever MA, (1994). Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-22
5. Bosch FX, Mano MM, Munoz N, Sherman M, (1995). Prevalence of human papilloma virus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute 87:796-802
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-12
7. Borysiewicz :LK, Fiander A.Nimako, Man S.Wilkinson GWG, Westmorland D, Evans AS, Adams M,Stacey SN, Boursnell MEG, Rutherford E, Hickling JK, Inglis SC. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18,E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-27.
8. Grabbe S,Beissert,Schwartz and Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunology Today 16(3) 117-121.
9. Gabrilovich DI Nadaf S,Corak J,Berzofsky JA and Carbonne DP (1996).Dendritic cells in anti-tumour immune responses 11 Dendritic cells grown from bone marrow precursors but not mature DC from tumour bearing mice are effective antigen carriers in the therapy of established tumours . Cellular Immunology 170, 111-119.